Vertically integrated cannabis company Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) announced its latest financial results Monday, revealing a 68% year-over-year jump in revenue to CA$2.8 million (CA$2.18 million) in the second quarter of 2021. Shares traded up 1.96% at $ 0.2499 per share in Friday's after-hours session.
The uptick in revenue during the quarter ended June 30 can be mainly attributed to normalized clinic operations and the growth of medical cannabis sales in Colombia, Germany, the UK
and Peru contributing to the gross medical cannabis profit margin of 88%.
Q2 2021 Financial Highlights
- Health Services revenues declined 13%, while medical cannabis revenues hit $825,500, up 47% sequentially.
- Medical cannabis products contributed 29% …